Kuros Biosciences AG Share Price Swiss Exchange
Equities
CH0011025217
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- CHF | - |
24/04 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
17/04 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Sales 2022 | 17.99M 19.87M 1.66B | Sales 2023 | 33.56M 37.07M 3.09B | Capitalization | 128M 142M 11.82B |
---|---|---|---|---|---|
Net income 2022 | -14M -15.46M -1.29B | Net income 2023 | -13M -14.36M -1.2B | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.39M 2.04B | Net cash position 2023 | 12M 13.25M 1.11B | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.71% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 04/17/04 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19/21/19 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 17/23/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 14/18/14 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19/21/19 |
Joost de Bruijn
FOU | Founder | 58 | 04/17/04 |
1st Jan change | Capi. | |
---|---|---|
-1.43% | 103B | |
+8.96% | 101B | |
+4.40% | 23.07B | |
-12.15% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.04% | 16.94B | |
+6.79% | 14.07B | |
+38.61% | 12.35B |